midazolam

Midazolam is a water-soluble benzodiazepine that binds to the benzodiazepine site on the GABA-A receptor, increasing the frequency of chloride channel opening, which enhances GABA's inhibitory effects on the CNS. This leads to sedation, anxiolysis, anterograde amnesia, muscle relaxation, and anticonvulsant effects. It is highly lipophilic at physiologic pH, allowing rapid CNS penetration and quick onset of action (1-5 minutes IV), with a short duration due to redistribution (elimination half-life ~2-6 hours, though prolonged in obese patients, elderly, or hepatic impairment due to its lipophilicity and CYP3A4 metabolism).

Clinical uses include: procedural/conscious sedation (endoscopy, minor surgery), preoperative anxiolysis, induction of general anesthesia, ICU sedation, status epilepticus (especially intranasal/intramuscular in pre-hospital settings), and alcohol withdrawal.

Key pharmacologic points for boards: - Metabolized by hepatic CYP3A4 to active metabolite (1-hydroxymidazolam), so drug interactions with CYP3A4 inhibitors (e.g., azole antifungals, macrolides) can prolong sedation. - Unlike other benzodiazepines, midazolam is water-soluble in acidic vials but becomes lipophilic at physiologic pH, explaining its fast onset. - Adverse effects: respiratory depression (especially with opioids), hypotension, paradoxical agitation (more common in children/elderly), and risk of oversedation in hepatic/renal impairment. - Reversal agent: flumazenil (competitive GABA-A/benzodiazepine receptor antagonist), used cautiously due to risk of seizures in chronic benzodiazepine users. - Contrast with diazepam (longer acting, active metabolites) and lorazepam (intermediate acting, no active metabolites, preferred in hepatic impairment).

High-yield board associations: benzodiazepine overdose triad (CNS depression, respiratory depression, hypotension), use in combination with opioids increasing respiratory depression risk, and its role in "conscious sedation" protocols.